Looking back at records of people with mitochondrial leukoencephalopathies
Reviews past health records of people with mitochondrial leukoencephalopathies to understand how the disease varies.
Key facts
- Who runs it
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
- Where
- Italy1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Natural History and Genotype-Phenotype Correlations in Mitochondrial Leukoencephalopathies
- Status
- Recruiting
- People taking part
- 100 people, planned
- Started
- 15 Sept 2025
- Expected to end
- Dec 2026
- Type of study
- Observational
- Record updated
- 9 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with a confirmed mitochondrial leukoencephalopathy, a genetic energy disorder that damages the brain's white matter. It studies existing medical records.
- Sex
- All sexes can join.
- Disease stage
- Diagnosis confirmed by an MRI pattern of white matter changes that fits leukoencephalopathy.
- Biomarker or test result
- A disease-causing gene change (pathogenic variant) in nuclear or mitochondrial genes.
Main reasons for not taking part
- Diagnosis not confirmed by MRI or by genetic testing.
- Medical records missing key details on symptom start, disease course, brain scans or care.
- Another genetic disorder that could also cause white matter damage or nerve symptoms.
- No written informed consent from the patient, guardian or next of kin.
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Confirmed diagnosis of ML, confirmed by:; Neuroradiological evidence of a MRI pattern of white matter alterations compatible with leukoencephalopathy; Genetic evidence of pathogenic variants in nuclear or mitochondrial genes
- Availability of clinical data, including medical records detailing symptom onset, disease progression, neuroimaging findings, and clinical management
- Written informed consent obtained from the patient or their legal guardian (for minors or individuals with cognitive impairment). If the patient is deceased, consent for the use of medical records in this study will be obtained from the legally authorized representative or next of kin
Who cannot take part
- Concomitant diagnosis of another genetic disorder that may independently contribute to white matter abnormalities or neurological symptoms, confounding the assessment of ML progression and clinical outcomes
- Insufficient clinical data, including cases where medical records lack essential information on symptom onset, disease progression, neuroimaging findings, or clinical management, preventing a meaningful contribution to the study's objectives
- Unconfirmed diagnosis of mitochondrial leukoencephalopathy , including cases where:; MRI findings do not demonstrate a white matter alteration pattern compatible with leukoencephalopathy; There is neither genetic confirmation of a pathogenic variant in nuclear or mitochondrial genes
- Unavailability of written informed consent
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Mitochondrial disorders (MDs) are among the most common inherited metabolic diseases, caused by genetic defects in mitochondrial or nuclear DNA that impair cellular energy production. The central nervous system (CNS) is frequently affected, due to its high energy demands. Within the broad clinical spectrum of MDs, mitochondrial leukoencephalopathies (MLs) have emerged as a distinct subgroup characterized by CNS white matter involvement.
Read full original descriptionShow less
MLs are clinically and genetically heterogeneous, with onset ranging from infancy to adulthood. Patients may experience episodes of neurological regression, often triggered by stressors such as febrile illnesses, alongside variable motor, cognitive, and occasionally extraneurological involvement. Neuroimaging typically reveals diffuse or focal white matter abnormalities, including cavitation and rarefaction, with additional involvement of deep gray matter structures. Certain ML subtypes exhibit characteristic MRI patterns that may aid in diagnosis.
Despite recent advancements in the genetic and neuroradiological characterization of MLs, significant knowledge gaps persist. Although the number of disease-causing genes has increased over the last decades, a comprehensive understanding of genotype-phenotype correlations is still lacking. Additionally, knowledge on the natural history of these disorders is limited. Existing data often focus on imaging findings with insufficient integration of clinical, biochemical, and molecular features, limiting the understanding of disease mechanisms, progression, and therapeutic responses.
In light of these gaps, this multicenter, observational, retrospective study aims to systematically collect and analyze clinical, biochemical, neuroradiological, and genetic data from individuals with MLs, assessed at international reference centers for MDs. The study seeks to better elucidate the phenotypic variability and genotype-phenotype correlations of MLs. This work is expected to enhance diagnostic accuracy, inform management strategies, support prognostic counseling, and ultimately contribute to the better overall management of affected individuals
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Natural History and Genotype-Phenotype Correlations in Mitochondrial Leukoencephalopathies: A Multicentric, International Observational Study
- Plain-language title
- Looking back at records of people with mitochondrial leukoencephalopathiesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 9 October 2026